This year, the Dutch Society for Clinical Pharmacology and Biopharmacy awards Annemarie Thijs with the 'NVKF&B Top Publication Prize 2014' for the publication entitled 'Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans' (Thijs, A. M., van Herpen, C. M., Sweep, F. C., Geurts-Moespot, A., Smits, P., van der Graaf, W. T. and Rongen, G. A. Hypertension 2013; 61:1060-1065).
Annemarie performed this study during her training as oncologist as part of her KWF-sponsored PhD project on the cardiovascular side effects of angiogenesis inhibitors. This project is a collaboration between the departments of Oncology and Pharmacology-Toxicology. In this publication, the anti-VEGF monoclonal antibody Bevacizumab was infused into the brachial artery of healthy volunteers to elucidate the role of endogenous VEGF in the maintenance of endothelial vascular control. Bevacizumab acutely reduced endothelium-dependent vasodilation, providing direct evidence in humans for a potential role of the endothelium in the hypertensive effect of VEGF-targeted anti-cancer therapies.
Since 2009 the Dutch Society for
Clinical Pharmacology and Biopharmacy selects the best clinical
pharmacological research that has been published in the previous
year for the NVKF&B Top Publication Prize. Since 2009, this
prize has been awarded twice to an investigator from the
Radboudumc. The previous winner from Nijmegen was Douwe Dekker with
his publication on the vascular actions of the bilirubin
-increasing drug atazanavir (Douwe Dekker, Mirrin J. Dorresteijn,
Margot Pijnenburg, Suzanne Heemskerk, Anja Rasing-Hoogveld, David
M. Burger, Frank A.D.T.G. Wagener, and Paul Smits. Arterioscler
Thromb Vasc Biol 2011;31:458-463.
Annemarie received the 2014 NVKF&B Top Publication Prize during the Figon-Dutch Medicine Days (6-8 oktober 2014, De ReeHorst, Ede; www.figondmd.nl)
<< back to overview news items